Plain-English translation of NCT06614686 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer treatment called U87, which is a type of immunotherapy that uses your own immune cells to fight cancer. Doctors will collect some of your white blood cells, modify them in a lab to better recognize and attack cancer cells, and then infuse them back into your body. This treatment is designed for people with advanced head and neck cancer whose cancer has not responded to standard therapy options.
Many people with advanced head and neck cancer run out of effective treatment options. Researchers believe this new personalized immune cell therapy might help by training the body's own immune system to recognize and destroy cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
First, doctors will test your tumor tissue to confirm you're a good candidate for this treatment. If you qualify, you'll undergo a procedure called leukapheresis, where blood is drawn to collect your white blood cells—this typically takes a few hours. Your cells are then sent to a lab to be modified over several weeks. Once the modified cells are ready, you'll receive chemotherapy to prepare your body, and then the new immune cells will be infused back into you. You'll need close follow-up visits to monitor how well the treatment works and watch for any side effects, with long-term safety monitoring continuing after treatment.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Enrollment target
~20 participants
Started
September 2024
Primary completion
October 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Haitao Wu, Ph.D
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.